Target intelligence / Profile preview

Covalently Closed Circular DNA (cccDNA)

Target: cccDNA
Molecular classification: DNA, Viral genome

Overview

Covalently closed circular DNA (cccDNA) is a unique, double-stranded DNA structure that forms during the life cycle of certain viruses, most notably hepatitis B virus (HBV). It acts as a stable template for viral transcription and plays a central role in viral persistence and chronic infection. Targeting cccDNA formation or maintenance is an area of intense therapeutic interest for chronic HBV infections.

Other names: Episomal DNAMinichromosome

Mechanism of action

Inhibition of cccDNA formation or maintenance

Biological functions

Viral RNA transcription templateViral replicationViral persistence

Disease associations

Hepatitis BChronic infectionViral persistence

Safety considerations

Potential for drug resistanceOff-target effects on host cell DNA repair mechanisms

Beyond the preview

Go deeper on Covalently Closed Circular DNA (cccDNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Covalently Closed Circular DNA (cccDNA).

Explore the full profile